GH Research PLC

NasdaqGM GHRS

GH Research PLC Total Assets for the year ending December 31, 2023: USD 226.30 M

GH Research PLC Total Assets is USD 226.30 M for the year ending December 31, 2023. Total assets are the total value of all assets owned by a company, representing its resources.

Key data

Date	Total Assets	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity

NasdaqGM: GHRS

GH Research PLC

CEO	Dr. Velichka Valcheva M.D.
IPO Date	June 25, 2021
Location	Ireland
Headquarters	28 Baggot Street Lower
Employees	49
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Research & Consulting

Description

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Key trends

Past 5 years